The metalloproteinase inhibitor GI5402 inhibits endotoxin-induced soluble CD27 and CD16 release in healthy humans.
Metalloproteinases have been implicated in the cleavage of a number of cell surface immune receptors. Oral administration of the metalloproteinase inhibitor GI5402 attenuated the release of soluble CD27 and CD16 into the circulation after intravenous endotoxin injection in healthy humans.
Dekkers
P E
PE
Laboratory of Experimental Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. P.E.Dekkers@AMC.UVA.NL
ten Hove
T
T
Lauw
F N
FN
Koene
H R
HR
Lumley
P
P
van Deventer
S J
SJ
van der Poll
T
T
D000328:Adult; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D006304:Health Status; D006801:Humans; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000276:immunology; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000276:immunology*; D017452:Receptors, IgG / Q000096:biosynthesis*; D012995:Solubility; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000096:biosynthesis*
D004791:Enzyme Inhibitors; D008070:Lipopolysaccharides; D061965:Matrix Metalloproteinase Inhibitors; D017452:Receptors, IgG; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D020782:Matrix Metalloproteinases